CPA
AKYA

Capital Performance Advisors’s Akoya BioSciences AKYA Stock Holding History

Capital Performance Advisors’s Portfolio AKYA Stock Details AKYA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-142
Closed -$386 – 254
2024
Q3 		$386 Buy
+142
New +$347 ﹤0.01% 2363

Other funds holding AKYA

BWLSA
Blue Water Life Science Advisors Larkspur, California $125M AUM 91.82% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAPAIJV
Paragon Associates & Paragon Associates II Joint Venture Dallas, Texas $73.6M AUM 61.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SW
SVB Wealth Boston, Massachusetts $1.59B AUM 24.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
PCA
Peddock Capital Advisors Braintree, Massachusetts $501M AUM 29.8% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Capital Performance Advisors's AKYA Position: Q4 2024 in Review

Capital Performance Advisors sold out of Akoya BioSciences (AKYA) in Q4 2024, closing a stake of 142 shares — an estimated $386 sold.

Capital Performance Advisors first reported a position in AKYA in Q3 2024 and held it in 1 quarter. The position peaked at $386 in Q3 2024. 61 funds tracked by Wall St. Rank hold AKYA as of Q4 2024.

  • Capital Performance Advisors reported no remaining Akoya BioSciences position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 142 Akoya BioSciences shares in Q4 2024, an estimated $386.
  • Capital Performance Advisors first reported a position in Akoya BioSciences in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's Akoya BioSciences position peaked at $386 in Q3 2024.
  • 61 funds tracked by Wall St. Rank held Akoya BioSciences as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.